Adenomyosis is associated with specific proton nuclear magnetic resonance (


Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
07 2021
Historique:
received: 04 07 2020
revised: 15 02 2021
accepted: 16 02 2021
pubmed: 15 4 2021
medline: 6 8 2021
entrez: 14 4 2021
Statut: ppublish

Résumé

To determine whether the adenomyosis phenotype affects the proton nuclear magnetic resonance ( Cohort study. University hospital-based research center. Seventy-seven patients who underwent laparoscopy for a benign gynecologic condition. Pelvic magnetic resonance imaging and collection of a venous peripheral blood sample were performed during the preoperative workup. The women were allocated to the adenomyosis group (n = 32), or the control group (n = 45). The adenomyosis group was further subdivided into two groups: diffuse adenomyosis of the inner myometrium (n = 14) and focal adenomyosis of the outer myometrium (n = 18). Other adenomyosis phenotypes were excluded. Metabolomic profiling based on The serum metabolic profiles of the patients with adenomyosis indicated lower concentrations of 3-hydroxybutyrate, glutamate, and serine compared with controls. Conversely, the concentrations of proline, choline, citrate, 2-hydroxybutyrate, and creatinine were higher in the adenomyosis group. The focal adenomyosis of the outer myometrium and the diffuse adenomyosis phenotypes also each exhibited a specific metabolic profile. Serum metabolic changes were detected in women with features of adenomyosis compared with their disease-free counterparts, and a number of specific metabolic pathways appear to be engaged according to the adenomyosis phenotype. The metabolites with altered levels are particularly involved in immune activation as well as cell proliferation and cell migration. Nevertheless, this study did find evidence of a correlation between metabolite levels and symptoms thought to be related to adenomyosis. Further studies are required to determine the clinical significance of these differences in metabolic profiles.

Identifiants

pubmed: 33849709
pii: S0015-0282(21)00149-7
doi: 10.1016/j.fertnstert.2021.02.031
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

243-254

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Mathilde Bourdon (M)

Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital universitaire Paris Centre, Paris, France; Department of Gynecology Obstetrics II and Reproductive Medicine, Cochin University Hospital Center, Paris, France; Department 3I "Infection, Immunité et inflammation," Cochin Institute, Institut national de la santé et de la recherche médicale U1016, Paris, France.

Pietro Santulli (P)

Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital universitaire Paris Centre, Paris, France; Department of Gynecology Obstetrics II and Reproductive Medicine, Cochin University Hospital Center, Paris, France; Department 3I "Infection, Immunité et inflammation," Cochin Institute, Institut national de la santé et de la recherche médicale U1016, Paris, France.

Fatiha Kateb (F)

Université de Paris, Faculty of Sciences, Campus Saint-Germain-des-Prés, Paris, France; Laboratory of Pharmacological and Toxicological Chemistry and Biochemistry, Unité mixte de recherche 8601-Centre national de la recherche scientifique, Paris, France.

Khaled Pocate-Cheriet (K)

Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital universitaire Paris Centre, Paris, France; Department 3I "Infection, Immunité et inflammation," Cochin Institute, Institut national de la santé et de la recherche médicale U1016, Paris, France; Department of Histology-Embryology and Reproductive Biology, Cochin University Hospital Center, Paris, France.

Frederic Batteux (F)

Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital universitaire Paris Centre, Paris, France; Department 3I "Infection, Immunité et inflammation," Cochin Institute, Institut national de la santé et de la recherche médicale U1016, Paris, France.

Chloé Maignien (C)

Assistance Publique-Hôpitaux de Paris, Hôpital universitaire Paris Centre, Paris, France; Department of Gynecology Obstetrics II and Reproductive Medicine, Cochin University Hospital Center, Paris, France.

Sandrine Chouzenoux (S)

Department 3I "Infection, Immunité et inflammation," Cochin Institute, Institut national de la santé et de la recherche médicale U1016, Paris, France.

Corinne Bordonne (C)

Assistance Publique-Hôpitaux de Paris, Hôpital universitaire Paris Centre, Paris, France; Department of Radiology, Hôtel-Dieu University Hospital Center, Paris, France.

Louis Marcellin (L)

Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital universitaire Paris Centre, Paris, France; Department of Gynecology Obstetrics II and Reproductive Medicine, Cochin University Hospital Center, Paris, France; Department 3I "Infection, Immunité et inflammation," Cochin Institute, Institut national de la santé et de la recherche médicale U1016, Paris, France.

Gildas Bertho (G)

Université de Paris, Faculty of Sciences, Campus Saint-Germain-des-Prés, Paris, France; Laboratory of Pharmacological and Toxicological Chemistry and Biochemistry, Unité mixte de recherche 8601-Centre national de la recherche scientifique, Paris, France. Electronic address: gildas.bertho@u-paris.fr.

Charles Chapron (C)

Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital universitaire Paris Centre, Paris, France; Department of Gynecology Obstetrics II and Reproductive Medicine, Cochin University Hospital Center, Paris, France; Department 3I "Infection, Immunité et inflammation," Cochin Institute, Institut national de la santé et de la recherche médicale U1016, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH